CAR-T cell manufacturing landscape—Lessons from the past decade and considerations for early clinical developmentJuliana Dias(Royal Free London NHS Foundation Trust), Claire Roddie(Cancer Institute (WIA))Molecular Therapy — Methods & Clinical DevelopmentApril 16, 202410.1016/j.omtm.2024.101250Cited by 76SaveCiteExport RISWatch citationsRelated PapersResults of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL|Blood Advances|2022|44Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes|Blood|2024|3Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel)|Transplantation and Cellular Therapy|2025|2